Meet Sanjay Ramakrishnan, COPD research specialist

The Institute is thrilled to welcome Sanjay Ramakrishnan, our newest team member. Hailing from a small town in Malaysia, Sanjay’s journey into the world of medicine was sparked by his dad, who happened to be a gynecologist. However, his trajectory took an unexpected turn when he stumbled upon the exciting realms of research and global perspectives at a British Council event.

Securing a scholarship to study Medicine at the University of Western Australia, Sanjay initially had his sights set on becoming a surgeon. Fate, however, had other plans for him. While interning with the respiratory researchers at Sir Charles Gairdner Hospital, he discovered a deep-seated passion for respiratory medicine.

Eager to challenge the stigma surrounding chronic obstructive pulmonary disease (COPD), Sanjay devoted his efforts to this area. Among his noteworthy achievements are leading the STOIC trial, which demonstrated the efficacy of inhaled budesonide in early COVID-19, and the STARR-2 trial, challenging the indiscriminate use of oral prednisolone for COPD exacerbations.

As part of his PhD journey, Sanjay conducted the ABRA trial, delving into the use of benralizumab for asthma and COPD exacerbations. If successful, this groundbreaking trial could mark the first instance of a monoclonal antibody being employed for any acute medical indication.

Currently engaged in post-doctoral research, Sanjay is on a mission to revolutionise COPD care. His focus is on enhancing diagnosis and implementing proactive interventions to predict and prevent COPD crises before they occur.

We are excited to have Sanjay Ramakrishnan on board, driving research innovation within our team.

Media contact:

Andrea Jones
Redhead Digital Marketing
Mobile – 0450613460